JP2014523444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523444A5 JP2014523444A5 JP2014521722A JP2014521722A JP2014523444A5 JP 2014523444 A5 JP2014523444 A5 JP 2014523444A5 JP 2014521722 A JP2014521722 A JP 2014521722A JP 2014521722 A JP2014521722 A JP 2014521722A JP 2014523444 A5 JP2014523444 A5 JP 2014523444A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocarrier
- lipid bilayer
- nanocarrier according
- group
- porous nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002539 nanocarrier Substances 0.000 claims description 26
- 239000000232 Lipid Bilayer Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 229930182558 Sterol Natural products 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 150000003432 sterols Chemical class 0.000 claims description 8
- 235000003702 sterols Nutrition 0.000 claims description 8
- -1 polyethylene Polymers 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 5
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 125000001095 phosphatidyl group Chemical group 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims description 2
- 240000002791 Brassica napus Species 0.000 claims description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 claims description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims description 2
- 244000188595 Brassica sinapistrum Species 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 229930183167 cerebroside Natural products 0.000 claims description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 150000004703 alkoxides Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108010035532 Collagen Chemical class 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 229920002494 Zein Polymers 0.000 claims 1
- 108010055615 Zein Proteins 0.000 claims 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229920003232 aliphatic polyester Polymers 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229920001436 collagen Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013980 iron oxide Nutrition 0.000 claims 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- UOXRPRZMAROFPH-IESLQMLBSA-N lysophosphatidylinositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O UOXRPRZMAROFPH-IESLQMLBSA-N 0.000 claims 1
- 150000001247 metal acetylides Chemical class 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 150000004767 nitrides Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical class [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000111 poly(butyric acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Chemical class 0.000 claims 1
- 239000005017 polysaccharide Chemical class 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 108060006613 prolamin Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003346 selenoethers Chemical class 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000000126 substance Chemical class 0.000 claims 1
- 229910001936 tantalum oxide Inorganic materials 0.000 claims 1
- 150000004772 tellurides Chemical class 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 229910052718 tin Inorganic materials 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 150000003623 transition metal compounds Chemical class 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 239000005019 zein Substances 0.000 claims 1
- 229940093612 zein Drugs 0.000 claims 1
- 229910052726 zirconium Inorganic materials 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229940033331 soy sterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509251P | 2011-07-19 | 2011-07-19 | |
| US61/509,251 | 2011-07-19 | ||
| PCT/US2012/047133 WO2013012891A1 (en) | 2011-07-19 | 2012-07-18 | Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523444A JP2014523444A (ja) | 2014-09-11 |
| JP2014523444A5 true JP2014523444A5 (https=) | 2015-09-10 |
Family
ID=47558435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014521722A Pending JP2014523444A (ja) | 2011-07-19 | 2012-07-18 | 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9532949B2 (https=) |
| EP (1) | EP2734191A4 (https=) |
| JP (1) | JP2014523444A (https=) |
| CN (1) | CN103917224A (https=) |
| AU (1) | AU2012284147A1 (https=) |
| BR (1) | BR112014001346A8 (https=) |
| CA (1) | CA2842306A1 (https=) |
| EA (1) | EA201490302A1 (https=) |
| WO (1) | WO2013012891A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9993437B2 (en) | 2007-12-06 | 2018-06-12 | The Regents Of The University Of California | Mesoporous silica nanoparticles for biomedical applications |
| ES2593027T3 (es) | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
| US8992984B1 (en) | 2009-10-21 | 2015-03-31 | Stc.Unm | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells |
| US20120207795A1 (en) | 2010-07-13 | 2012-08-16 | The Regents Of The University Of California | Cationic polymer coated mesoporous silica nanoparticles and uses thereof |
| AU2012249474A1 (en) | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| US10220004B2 (en) | 2011-07-14 | 2019-03-05 | The Regents Of The University Of California | Method of controlled delivery using sub-micron-scale machines |
| BR112014001346A8 (pt) | 2011-07-19 | 2018-05-08 | Stc Unm | composto nanotransportador, método, composto farmacêutico e uso de um composto |
| US9687569B2 (en) | 2012-08-16 | 2017-06-27 | University Of Washington Through Its Center For Commercialization | Theranostic nanoparticle and methods for making and using the nanoparticle |
| EP4378461A3 (en) * | 2013-03-05 | 2024-09-11 | The Regents of University of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| CN103611172B (zh) * | 2013-12-02 | 2015-06-03 | 东南大学 | 载纳米雄黄磁性白蛋白纳米球及制备方法 |
| CN103919803B (zh) * | 2014-04-16 | 2018-07-31 | 厦门大学 | 一种装载砷剂的抗癌纳米药物及其制备方法 |
| WO2016044716A1 (en) * | 2014-09-19 | 2016-03-24 | The American University In Cairo | Nanoparticle-based combinatorial therapy |
| CN107921005A (zh) * | 2015-02-13 | 2018-04-17 | 友杏生技医药股份有限公司 | 利用纳米颗粒治疗肿瘤的组合物和方法 |
| CA2977397A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
| JP2018530623A (ja) * | 2015-10-15 | 2018-10-18 | リポメディックス・ファーマシューティカルズ・リミテッドＬｉｐｏｍｅｄｉｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． | ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物 |
| US20180369422A1 (en) * | 2015-12-31 | 2018-12-27 | City Of Hope | Nanoparticles for cancer detection |
| US11672866B2 (en) | 2016-01-08 | 2023-06-13 | Paul N. DURFEE | Osteotropic nanoparticles for prevention or treatment of bone metastases |
| CN108601746B (zh) | 2016-01-08 | 2024-09-13 | 加利福尼亚大学董事会 | 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒 |
| US12029724B2 (en) * | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| CN107362142B (zh) * | 2016-05-13 | 2023-04-25 | 山东新时代药业有限公司 | 一种氟维司群脂质体注射液及其制备方法 |
| JP7549306B2 (ja) * | 2016-07-22 | 2024-09-11 | 株式会社リピドームラボ | 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発 |
| AU2017327392B9 (en) * | 2016-09-13 | 2023-10-12 | Tiziana Life Sciences Plc | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| CN106943378B (zh) * | 2017-02-16 | 2020-09-15 | 上海交通大学 | 红细胞膜包封聚酯类载三氧化二砷纳米粒及其制备方法 |
| WO2018160865A1 (en) | 2017-03-01 | 2018-09-07 | Charles Jeffrey Brinker | Active targeting of cells by monosized protocells |
| CN107096037B (zh) * | 2017-04-11 | 2019-12-31 | 同济大学 | 一种酶促小分子自组装制备纳米凝胶的方法 |
| CN107213479B (zh) * | 2017-06-22 | 2018-12-28 | 苏州杰纳生物科技有限公司 | 一种包含过氧化氢酶的组合物及用途 |
| CN108014094A (zh) * | 2017-12-26 | 2018-05-11 | 厦门大学 | 一种含顺铂和砷剂的纳米药物及其制备方法 |
| US12383499B2 (en) | 2018-01-01 | 2025-08-12 | The Regents Of The University Of California | Scale up synthesis of silicasome nanocarriers |
| WO2019213270A1 (en) * | 2018-05-01 | 2019-11-07 | Rutgers, The State University Of New Jersey | Benzalkonium-embedded mesostructured silica compositions and uses of same |
| WO2020068798A1 (en) | 2018-09-24 | 2020-04-02 | Guo Jimin | Living mammalian cells modified with functional modular nanoparticles |
| MX2021005110A (es) * | 2018-11-02 | 2021-08-24 | Tesorx Pharma Llc | Quimioterapia intraperitoneal mejorada con liposomas. |
| TR201820952A2 (tr) * | 2018-12-28 | 2020-07-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Granülosi̇t koloni̇ uyarici faktör i̇çeren bi̇r kombi̇nasyon |
| US12208164B2 (en) | 2019-02-28 | 2025-01-28 | Unm Rainforest Innovations | Modular metal-organic polyhedra superassembly compositions |
| US11207348B2 (en) | 2019-04-25 | 2021-12-28 | Imam Abdulrahman Bin Faisal University | Spinel ferrite impregnated mesoporous silica containing a platinum complex |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN110448541B (zh) * | 2019-08-02 | 2021-10-01 | 中山大学 | 双功能化纳米粒、可溶性微针及其制备方法与应用 |
| CN114686416B (zh) * | 2020-12-30 | 2024-03-19 | 湖南大学 | 一种膜融合脂质体及其应用 |
| US11779652B2 (en) | 2021-06-18 | 2023-10-10 | Imam Abdulrahman Bin Faisal University | Porous silicate/magnetic ferrite nanocarrier for combination anti-cancer therapeutic and antioxidant delivery |
| CN114031048B (zh) * | 2021-11-09 | 2024-03-15 | 广州天科生物科技有限公司 | 一种纳米硒的制备方法 |
| CN115089728B (zh) * | 2022-06-16 | 2024-01-26 | 磐如生物科技(天津)有限公司 | 一种膀胱癌靶向纳米药物及其制备方法 |
| CN115105584B (zh) * | 2022-06-28 | 2023-03-31 | 长春生物制品研究所有限责任公司 | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5277913A (en) | 1991-09-09 | 1994-01-11 | Thompson David H | Liposomal delivery system with photoactivatable triggered release |
| US5820879A (en) * | 1993-02-12 | 1998-10-13 | Access Pharmaceuticals, Inc. | Method of delivering a lipid-coated condensed-phase microparticle composition |
| ATE209887T1 (de) * | 1993-04-02 | 2001-12-15 | Anticancer Inc | Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel |
| US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| US6264741B1 (en) | 1998-11-25 | 2001-07-24 | Sandia Corporation | Self-assembly of nanocomposite materials |
| US6350464B1 (en) * | 1999-01-11 | 2002-02-26 | Guilford Pharmaceuticals, Inc. | Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
| WO2003016040A1 (en) | 2001-04-16 | 2003-02-27 | The Regents Of The University Of California | Membrane mimetic architectures on nanoporous materials |
| US20060177495A1 (en) | 2001-12-21 | 2006-08-10 | Christine Allen | Polymer-lipid delivery vehicles |
| US20040005352A1 (en) | 2002-04-16 | 2004-01-08 | Lopez Gabriel P. | Biologically functionalized porous microspheres |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| US7563451B2 (en) | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
| US20070037751A1 (en) * | 2003-08-06 | 2007-02-15 | Gastrotech Pharma A/S | Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| KR20070110084A (ko) | 2005-02-14 | 2007-11-15 | 오스트레일리언뉴클리어사이언스앤드테크놀로지오거나이제이션 | 층상 나노입자 |
| US7514267B1 (en) | 2005-08-19 | 2009-04-07 | Stcunm | Detection systems utilizing supported lipid bilayers |
| US20080160313A1 (en) | 2006-04-26 | 2008-07-03 | Gabriel Lopez | Lipid bilayers on nanotextured solid surfaces |
| MX2009001533A (es) * | 2006-08-11 | 2009-02-18 | Panacea Biotec Ltd | Particulas para el suministro de ingredientes activos, procedimiento de elaboracion y sus composiciones. |
| EP2099496A2 (en) | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
| US20080279764A1 (en) * | 2007-03-09 | 2008-11-13 | Anthony Manganaro | Method and composition for treating cancer |
| CA2702103A1 (en) | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| US9993437B2 (en) | 2007-12-06 | 2018-06-12 | The Regents Of The University Of California | Mesoporous silica nanoparticles for biomedical applications |
| US20110105995A1 (en) * | 2008-01-16 | 2011-05-05 | Zhu Ting F | Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery |
| US8962344B2 (en) | 2008-03-16 | 2015-02-24 | Synamem Corporation | Membrane-coated particles |
| CA2722183C (en) | 2008-04-25 | 2018-09-18 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| JP5366612B2 (ja) | 2008-05-20 | 2013-12-11 | 株式会社東芝 | 画像処理装置、画像処理方法および画像処理プログラム |
| CN101658533A (zh) | 2008-08-29 | 2010-03-03 | 首都医科大学宣武医院 | 抗肿瘤药物的干细胞递送 |
| WO2010078569A2 (en) | 2009-01-05 | 2010-07-08 | Stc.Unm | Porous nanoparticle supported lipid bilayer nanostructures |
| US8992984B1 (en) | 2009-10-21 | 2015-03-31 | Stc.Unm | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells |
| US20130017210A1 (en) | 2010-03-17 | 2013-01-17 | Stc.Unm | Display of antibody fragments on virus-like particles of rna bacteriophages |
| US20110300186A1 (en) | 2010-04-14 | 2011-12-08 | Battelle Memorial Institute | Functionalized Nano- and Micro-materials for Medical Therapies |
| AU2012249474A1 (en) | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| BR112014001346A8 (pt) | 2011-07-19 | 2018-05-08 | Stc Unm | composto nanotransportador, método, composto farmacêutico e uso de um composto |
| JP2014532071A (ja) | 2011-10-14 | 2014-12-04 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 |
| WO2013103614A1 (en) | 2011-12-30 | 2013-07-11 | Stc.Unm | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) |
| US20160151482A1 (en) | 2013-04-02 | 2016-06-02 | Stc. Unm | Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery |
| WO2014165608A1 (en) | 2013-04-02 | 2014-10-09 | Stc. Unm | Antibiotic protocells and related pharmaceutical formulations and methods of treatment |
| EP3046543A1 (en) | 2013-09-18 | 2016-07-27 | Stc.Unm | Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells |
| WO2015042268A1 (en) | 2013-09-18 | 2015-03-26 | Stc.Unm | Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo |
-
2012
- 2012-07-18 BR BR112014001346A patent/BR112014001346A8/pt not_active IP Right Cessation
- 2012-07-18 CA CA2842306A patent/CA2842306A1/en not_active Abandoned
- 2012-07-18 CN CN201280045672.3A patent/CN103917224A/zh active Pending
- 2012-07-18 US US14/233,527 patent/US9532949B2/en not_active Expired - Fee Related
- 2012-07-18 WO PCT/US2012/047133 patent/WO2013012891A1/en not_active Ceased
- 2012-07-18 JP JP2014521722A patent/JP2014523444A/ja active Pending
- 2012-07-18 AU AU2012284147A patent/AU2012284147A1/en not_active Abandoned
- 2012-07-18 EA EA201490302A patent/EA201490302A1/ru unknown
- 2012-07-18 EP EP12815024.0A patent/EP2734191A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523444A5 (https=) | ||
| Singh et al. | Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation | |
| Suchyta et al. | Controlled release of nitric oxide from liposomes | |
| JP2014532665A5 (https=) | ||
| KR101802553B1 (ko) | 제약 생성물을 패키지 표면 상에 직접적으로 형성시키는 방법 및 시스템 | |
| Conte et al. | Polyphenols nanoencapsulation for therapeutic applications | |
| Niaz et al. | Antihypertensive nano-ceuticales based on chitosan biopolymer: Physico-chemical evaluation and release kinetics | |
| Ebabe Elle et al. | Functionalized mesoporous silica nanoparticle with antioxidants as a new carrier that generates lower oxidative stress impact on cells | |
| TW200902085A (en) | Liposome for pulmonary administration to control drug delivery | |
| CN103917224A (zh) | 基于在癌症的炎症环境释放治疗性负载的腹膜内给药的纳米载体 | |
| JP6705933B2 (ja) | リポソーム組成物およびその製造方法 | |
| Sun et al. | Alendronate PtIV prodrug amphiphile for enhanced chemotherapy targeting and bone destruction inhibition in osteosarcoma | |
| WO2013105026A4 (en) | A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins | |
| CN108289833A (zh) | 用于递送囊封剂的稳定的已组装纳米结构 | |
| Goshisht et al. | Recent advances in biomedical applications of smart nanomaterials: A comprehensive review | |
| Cano‐Sarabia et al. | Lipid/ZIF‐8 Biocomposites Based on Liposomes or Vesicles: In Situ Formation, and Preliminary Evaluation as Delivery Vehicles for Hydrophobic Drugs | |
| CA2483916C (en) | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs | |
| CN102626390B (zh) | 一种天麻素多相脂质体注射液 | |
| Zhang et al. | Hydroxyapatite-based nano-drug delivery system for nicotinamide mononucleotide (NMN): significantly enhancing NMN bioavailability and replenishing in vivo nicotinamide adenine dinucleotide (NAD+) levels | |
| KR100823345B1 (ko) | 코엔자임 큐텐을 포함하는 나노크기의 리포좀 에멀젼을 담지한 실리카 및 그의 제조방법 | |
| US20130189347A1 (en) | Disease treatment drug | |
| Veerapu et al. | Review on novel carrier system: liposomes and proliposomes | |
| US20060029656A1 (en) | Replacement enzyme cochleates | |
| Pérez-Martínez et al. | Nanotechnology as a potential tool against drug-and multidrug-resistant tuberculosis | |
| US20070212403A1 (en) | Method for Selecting Cationic or Anionic Liposomes for Treatment of a Mucosa Membrane, and Kit Comprising the Same |